Plegridy Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing prevalence of multiple sclerosis diagnoses, availability of interferon-based therapies, expansion of neurology specialty clinics, growth in injectable biologic treatments, regulatory approvals for pegylated therapies.

The growth in the forecast period can be attributed to increasing demand for improved patient adherence solutions, rising investments in ms drug innovation, expansion of personalized neurology care, growing focus on long-term disease management, advancements in biologic drug delivery systems. Major trends in the forecast period include increasing adoption of long-acting ms therapies, rising demand for reduced injection frequency treatments, growing focus on disease-modifying therapies, expansion of patient-centric treatment models, enhanced monitoring of treatment outcomes.

The increasing prevalence of multiple sclerosis is expected to support the expansion of the plegridy market in the coming years. Multiple sclerosis is a chronic autoimmune condition in which the immune system attacks myelin, the protective coating of nerve fibers in the central nervous system, disrupting communication between the brain and the body and causing a range of neurological symptoms. The rising prevalence of multiple sclerosis is linked to environmental influences, improved diagnostic capabilities, greater disease awareness and recognition, and lifestyle-related factors such as obesity and vitamin D deficiency, particularly among women. Plegridy is prescribed to patients with multiple sclerosis to help reduce relapse frequency and slow disease progression through immune system modulation. For instance, in May 2024, according to a report by the Multiple Sclerosis Trust, a UK-based national charity, more than 150,000 people in the UK are living with multiple sclerosis, with over 7,100 new diagnoses recorded annually. Additionally, cases have increased by up to 15% across regions and are most commonly diagnosed in individuals in their 30s and 40s. Therefore, the growing prevalence of multiple sclerosis is driving the growth of the plegridy market.

The expanding adoption of biologics is anticipated to contribute to the growth of the plegridy market in the future. Biologics are advanced therapies derived from living organisms, such as proteins and antibodies, designed to treat diseases by precisely targeting specific biological pathways. Their increasing adoption is driven by proven effectiveness across multiple conditions, ongoing advancements in biotechnology, and rising demand for targeted treatments that address complex diseases. In multiple sclerosis therapy, biologics have supported plegridy’s growth by providing patients with a more targeted, effective, and convenient treatment option. For example, in August 2025, according to the National Institutes of Health (NIH), a US-based biomedical research organization, the FDA approved 50 new drugs in 2024, including 16 biologics, with six biologic approvals occurring in the first half of the year. Consequently, the growing use of biologics is contributing to the expansion of the plegridy market.

The rise in healthcare spending is expected to drive the growth of the plegridy market going forward. Healthcare spending encompasses total expenditures on healthcare services and products, including personal medical care, preventive services, public health programs, and healthcare administration, aimed at improving overall health outcomes. Increased healthcare spending is fueled by population growth, an aging demographic, higher prevalence of chronic diseases, and rising costs of medical services and prescription medications. Higher healthcare expenditure supports plegridy adoption by improving access to treatment, increasing patient awareness, and strengthening healthcare infrastructure for multiple sclerosis management. For instance, in August 2023, according to a report from the National Health Service Confederation, a UK-based membership organization, NHS England received a total allocation of $152.6 billion for the 2022-23 fiscal year, with $107.8 billion, representing more than 70% of the budget, directed to integrated care boards. Therefore, the increase in healthcare spending is driving the growth of the plegridy market.

Major companies operating in the plegridy market are Biogen Inc.

North America was the largest region in the plegridy market in 2025. The regions covered in the plegridy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plegridy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the plegridy market by increasing costs of imported active pharmaceutical ingredients, biologic manufacturing inputs, prefilled injection devices, and specialized packaging materials. Healthcare systems in North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces pricing pressures in specialty drug distribution. These tariffs are contributing to higher therapy costs and influencing reimbursement negotiations. However, they are also encouraging regional biologics production, localized filling and packaging operations, and increased investment in domestic pharmaceutical manufacturing capacity.

The plegridy market research report is one of a series of new reports that provides plegridy market statistics, including plegridy industry global market size, regional shares, competitors with a plegridy market share, detailed plegridy market segments, market trends and opportunities, and any further data you may need to thrive in the plegridy industry. This plegridy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plegridy (generic name: peginterferon beta-1a) is a prescription drug used in the treatment of relapsing forms of multiple sclerosis (MS), a long-term condition that affects the central nervous system. It works by lowering the rate of relapses and helping to slow the progression of physical disability in individuals with MS.

The primary routes of administration for Plegridy are subcutaneous (SC) and intramuscular (IM) injections. A subcutaneous injection delivers the medication into the fatty tissue beneath the skin using a short needle. This approach is often selected for its convenience and the gradual release of the drug into the bloodstream. Plegridy is administered via subcutaneous injection, enabling patients to manage their treatment independently. This route is especially appropriate for clinical indications such as relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS). The drug is distributed through multiple channels, including direct sales, online pharmacies, and wholesale distributors, and is used by hospitals and clinical research laboratories.

The plegridy market consists of sales of plegridy (peginterferon beta-1a) injection and auto-injectors (plegridy pen). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.